The Jerusalem-based company KAHR Medical Ltd has developed novel fusion protein pharmaceuticals for the treatment of cancer and autoimmune diseases. According to the report, Korean Investment Partners financed KAHR to initiate a Phase-I/IIa trial in lymphoma treatment.